Publication | Open Access

A Phase I Study to Evaluate Two Doses of Wharton’s Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease

Regenerative MedicineCell TherapyTransplantationMedicineStem Cell TransplantationImmunologyWharton ’Stem Cell ResearchStem-cell TherapyStem Cell TherapiesBiomedical EngineeringDermatologyDe Novo High-riskMesenchymal Stem CellStem CellsCell Transplantation